Chiesi Highlights Innovations in Respiratory Care at Recent Event
Chiesi recently participated in an event showcasing advancements in respiratory care, with a strong focus on biomarkers and digital technologies. A key session, “Transform Asthma Management,” explored improving long-term disease control and reducing exacerbations through combining extrafine therapy with evidence-based practices, specifically targeting the small airway and identifying treatable features.
Beyond symposia, Chiesi hosted six live sessions at its stand, dedicated to discussions around innovation, patient experience, and sustainability in respiratory treatment.The company also collaborated with academic institutions and scientific societies on two joint sessions, addressing the management of bronchiectasis and the importance of optimal inhalation techniques for therapeutic efficacy.
Chiesi presented over 50 abstracts stemming from its own research and collaborative studies, solidifying its position as a leader in respiratory research. Notable advancements included the development of precision medicine tools utilizing precision pulmonary cuts (PCLS) and artificial intelligence (AI)-enhanced imaging, aiming to optimize treatment selection and enable earlier diagnosis of lung alterations.
The company also shared data on biomarkers used to identify asthma exacerbation phenotypes and airway remodeling,leveraging advanced image and transcriptomic techniques. Digital health solutions were also introduced, including Epro (electronically reported patient outcomes) and automatic learning models for asthma diagnosis and monitoring, facilitating personalized medicine and remote patient management.
Michelle Soriano, Executive Vice President from Air Franchise In Chies, emphasized the need for a holistic approach to respiratory care, extending beyond new treatments to encompass equitable access to diagnosis, proper inhaler selection, and optimized therapeutic strategies.
Chiesi’s commitment to sustainability is underscored by its status as a Certified B Corp as 2019. The company aims to achieve greenhouse gas emission neutrality by 2035,integrating scientific innovation with corporate responsibility.
With over 90 years of experience and a presence in 31 countries, Chiesi is establishing itself as a pivotal force in the evolution of respiratory medicine, combining cutting-edge science, digital technologies, and environmental responsibility to enhance the lives of patients with chronic pulmonary diseases.
